Hai-ru CAO, Xiao LONG, Zhi-fei LIU, Ang ZENG, Ming BAI, Xiao-jun WANG. Safety and Efficacy of Cross-linked Hyaluronic Acid Revanesse Ultra for Treatment of Nasolabial Folds[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(2): 88-92. DOI: 10.3969/j.issn.1674-9081.2016.02.002
Citation: Hai-ru CAO, Xiao LONG, Zhi-fei LIU, Ang ZENG, Ming BAI, Xiao-jun WANG. Safety and Efficacy of Cross-linked Hyaluronic Acid Revanesse Ultra for Treatment of Nasolabial Folds[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(2): 88-92. DOI: 10.3969/j.issn.1674-9081.2016.02.002

Safety and Efficacy of Cross-linked Hyaluronic Acid Revanesse Ultra for Treatment of Nasolabial Folds

More Information
  • Corresponding author:

    WANG Xiao-jun Tel: 010-69158975, E-mail:pumchwxj@163.com

  • Received Date: January 26, 2015
  • Issue Publish Date: March 29, 2016
  •   Objective  To evaluate the safety and efficacy of cross-linked hyaluronic acid Revanesse Ultra for treatment of nasolabial folds in Chinese population.
      Methods  A total of 120 participants were enrolled in this prospective, randomized, positive controlled, non-inferiority clinical trial in accordance to inclusion and exclusion criteria, and signed informed consents were obtained. The participants were numbered in the order of enrollment and randomized into Restylane group and Revanesse group, receiving hyaluronic acid injection to correct bilateral nasolabial folds. Each person received 1 or 2 times of injection (a touch-up injection could be administered 4 weeks post the first injection). According to the original depth of the wrinkles, no more than 2 ml hyaluronic acid was injected into each side. All the participants were followed up at 1, 3, 6, and 12 months after the last injection and standardized photographs were taken at each visit. All the participants were asked to fill the form of local adverse events within the first 15 days after injection. Investigators and the participants both evaluated wrinkles based on Wrinkle Severity Rating Scale (WSRS). The WSRS score according to the pictures of 6 months post-injection were compared with the pictures which were taken before the injection (baseline) by independent staff at the end of the trial. One or more grades of WSRS improvement compared with the baseline was considered as effective. Laboratory tests including blood and urine routine, liver and renal function tests were carried out at screening visit and 6 months after injection.
      Results  The baseline features between the two groups were comparable (all P > 0.05). There was no significant difference in the WSRS 6 months after injection between the two groups (P > 0.05). There was no significant difference in the WSRS improvement compared with baseline between the two groups (P=0.105). There was no significant difference in the rate of effectiveness between the two groups (93.0% vs. 96.7%, P=0.431). Two participants reported minor adverse events, although both of which might not be associated with the product or procedure. No laboratory test change was found during the trial.
      Conclusions  No severe adverse event associated with the injection material was observed during this clinical trial. According to the result, Revanesse Ultra may have good histocompatibility and tolerance. It could provide obvious improvement in the nasolabial folds, with effectiveness comparable to that of Restylane.
  • [1]
    Hotta T. Dermal fillers. The next generation[J].Plast Surg Nurs, 2004, 24:14-19. DOI: 10.1097/00006527-200401000-00006
    [2]
    França Wanick FB, Almeida Issa MC, Luiz RR, et al. Skin remodeling using hyaluronic acid filler injections in photo-aged faces[J]. Dermatol Surg, 2016, 42:352-359. DOI: 10.1097/DSS.0000000000000659
    [3]
    Roh NK, Kim MJ, Lee YW, et al. A split-face study of the effects of a stabilized hyaluronic acid-based gel of nonanimal origin for facial skin rejuvenation using a stamp-type multineedle injector:a randomized clinical trial[J]. Plast Reconstr Surg, 2016, 137:809-816. DOI: 10.1097/01.prs.0000480686.68275.60
  • Related Articles

    [1]ZHANG Zhanjie, XIAO Yunqing, CHANG Qing, PAN Hui, ZHOU Jiong, GAO Jingsong, ZHANG Yu, MA Xiaojun. Strengthening the Maternal Health Management System to Safeguard Regional Maternal and Child Safety[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2025-0118
    [2]ZHENG Jiaojie, ZHANG Mingzi, SI Loubin, CHEN Jie, WANG Xiaojun, LONG Xiao, XIONG Wei. Journey and Significance of Quality Control in Medical Safety for China's Plastic Surgery and Aesthetic Medicine Professions[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1233-1237. DOI: 10.12290/xhyxzz.024-0487
    [3]ZHOU Jiong, WANG Shuchang, MA Xiaojun. Improving Medical Quality and Safety Through DRG Payment Model[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 981-986. DOI: 10.12290/xhyxzz.2024-0479
    [4]ZHANG Yu, ZHAO Mengyun, PEI Lijian, GONG Yahong, RUAN Xia, ZHANG Yuguan, XIA Di, LU Zhilong, ZHANG Zhanjie, ZHOU Jiong, FU Chenwei, GAO Jinsong, HUANG Yuguang. Epidural Labor Analgesia: Comfort and Safety Run in Parallel, with Teaching and Quality Control Complementing Each Other[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 246-250. DOI: 10.12290/xhyxzz.2024-0026
    [5]ZHENG Jiaojie, ZHANG Mingzi, SI Loubin, CHEN Jie, WANG Xiaojun, LONG Xiao, XIONG Wei. The Journey and Significance of Quality Control in Medical Safety for China's Plastic Surgery and Aesthetic Medicine Professions[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0487
    [6]WEI Mengchao, WANG Wenda, WANG Shijun, ZHANG Zhijun, WEN Jin. Preliminary Efficacy of Combined Laparoscopy and Cystoscopy in the Treatment of Bladder Diverticula[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 802-807. DOI: 10.12290/xhyxzz.2023-0044
    [7]HE Liyun, ZHANG Huabing, LI Yuxiu. Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 948-952. DOI: 10.12290/xhyxzz.2022-0391
    [8]SUN Wenjuan, ZOU Yuzhen, ZHANG Fan, ZHANG Lu, ZHAO Lin, BAI Chunmei, ZHANG Feng, XU Yan, MAO Feng, LI Jing, GU Yu, FAN Xinrong, WANG Mengzhao, ZHOU Daobin, ZHANG Zhanjie, ZHAO Bin, DU Xiaoli, ZHANG Bo, SUN Xueqin, LONG Xiao, CHANG Qing, HU Bingshui, PAN Hui, WU Wenming. Design and Analysis of the Operation Effect of the Safety Management System for Antitumor Drugs[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 461-467. DOI: 10.12290/xhyxzz.2021-0704
    [9]De-qian MENG, Lu LI, Jin-jing LIU, Di WU, Nan JIANG, Yun-jiao YANG, Jia-xin ZHOU, Li WANG, Xiao-feng ZENG, Feng-chun ZHANG, Wen-jie ZHENG. Therapeutic Effect of Infliximab in the Treatment of Severe/Refractory Intestinal Behcet's Disease: A Single-center Retrospective Study[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 237-242. DOI: 10.3969/j.issn.1674-9081.2019.03.009
    [10]Jing WEI, Li-li SHI, Jin-ya CAO. Systematic Assessment and Intervention of Mental Health Status Should Be Integrated into Patient Safety Management[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 206-210. DOI: 10.3969/j.issn.1674-9081.2019.03.004
  • Cited by

    Periodical cited type(5)

    1. 苗丽晓,杨超,马建彩,张丽娜,李瑞雪,杨丽萍. 子痫前期并发幽门螺杆菌感染血清miR-31-5p、miR-4286表达及意义. 中华医院感染学杂志. 2024(13): 2032-2036 .
    2. 苏加碧,李姝静,谢飞,丁文. 幽门螺杆菌感染对妊娠期糖尿病患者血糖、血脂的影响. 中国现代药物应用. 2024(22): 67-69 .
    3. 于艳,白青山,才蔚涛. 子痫前期并发幽门螺旋杆菌感染患者血清miR-31-5p表达与不良妊娠结局的相关性研究. 现代检验医学杂志. 2022(01): 17-20+32 .
    4. 于艳,白青山,才蔚涛,高慧. 血清微小核糖核酸-4286与幽门螺旋杆菌感染的子痫前期患者妊娠结局的关系. 生物医学工程与临床. 2022(06): 755-760 .
    5. 范梦迪,李青菊,李俊,付威. 幽门螺旋杆菌感染对妊娠期糖尿病患者妊娠结局的影响. 实用医学杂志. 2021(04): 468-471 .

    Other cited types(3)

Catalog

    Article Metrics

    Article views (113) PDF downloads (11) Cited by(8)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close